Advanced Enzyme Technologies Limited extinguished 8,25,028 equity shares in September 2026. The reduction follows the company's ongoing buyback programme executed through the open market route.

The shares, each with a face value of ₹2, were purchased during August 2026. Central Depository Services (India) Limited processed the extinguishment on September 2, 2026. The company notified the stock exchanges on September 8, 2026.

Transaction Details

The extinguishment was carried out entirely in dematerialized form. No physical share certificates were cancelled as part of this specific transaction batch.

Regulatory Compliance

The action complies with Regulations 11 and 21 of the SEBI (Buy-Back of Securities) Regulations, 2018. Shiv Hari Jalan & Co., the secretarial auditor, issued a certificate confirming compliance. The firm verified that the number of shares bought back matched those extinguished by CDSL.

Mukund Kabra, Whole-time Director, and Vinodkumar Jajoo, Independent Director, signed the certificate on behalf of the board. Sanjay Basantani, Company Secretary, filed the disclosure with BSE and NSE.

Advanced Enzyme Technologies Limited has uploaded the full transcript of the conference call held with analysts and investors to discuss its unaudited financial results for the quarter ended June 30, 2026 (Q1FY27). The call took place on Wednesday, August 12, 2026, and was moderated by Akash from Door Sabha. The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Context

During the quarter, Advanced Enzyme Technologies reported a consolidated net profit of ₹386 million, a 5% decline from ₹404 million in Q1FY26. Revenue from operations grew by 2% to ₹1,898 million. However, EBITDA fell 10% year-on-year to ₹510 million, compressing the EBITDA margin to 27% from 30%. This margin pressure was driven by declines in the Human and Animal Nutrition segments, despite growth in Bio-Processing and Specialized Manufacturing.

Management Commentary

Mukund Kabra, Whole-time Director, attributed the muted start to the fiscal year to global geopolitical tensions and supply chain disruptions, which impacted energy and raw material pricing. He highlighted that the top-line growth of 2% was impacted by an additional sales reversal of ₹100 million due to revenue recognition principles regarding goods in transit. Without this reversal, revenue would have been approximately ₹1,998 million, representing roughly 8% growth over the prior year's base.

Kabba noted that while the Human Healthcare segment saw a 7% YoY decline in revenue to ₹1,139 million, the Bioprocessing segment delivered strong 30% YoY growth to ₹306 million, driven by the food business. Specialized Manufacturing also posted robust 41% YoY growth to ₹200 million.

Beni Rauka, Group Chief Financial Officer, elaborated on the cost structure, noting that elevated power and fuel costs contributed to the margin contraction. He stated that consolidated debt stands at about 20% of revenue, down from 22% in Q1FY26. Rauka also provided subsidiary performance details: JC Biotech reported revenue of ₹195 million and PAT of ₹10 million, while Evoxx reported revenue of ₹74 million but incurred a negative PAT of ₹18 million. SciTech, another subsidiary, saw its revenue rise to ₹201 million with a PAT of ₹13 million, compared to a loss in the prior year.

Strategic Updates

The Board has approved a buyback of ₹697 million at a ceiling price of ₹500 per share via the open market route. Additionally, the company announced the acquisition of the remaining 4.28% stake in JC Biotech for ₹79.79 million, making it a wholly-owned subsidiary.

Regarding capital expenditure, Rauka confirmed an outlay of ₹123 crore for FY27, with approximately ₹50 crore allocated to R&D and the remainder for growth initiatives. He noted that fermentation utilization is close to 70-75%, necessitating capacity expansion plans.

US Market Challenges

Management addressed questions regarding the sluggish growth in the US market. Rauka explained that the business is undergoing a strategic shift towards branding products rather than selling unbranded ingredients, a process taking time to consolidate. Geopolitical issues and logistical challenges have further complicated operations. The company expects steady-state growth of 8-10% in the US business once these transitions stabilize.

Next Steps

The audio recording of the conference call was previously uploaded on August 12, 2026. The transcript is now available on the company’s investor relations page. The information was filed with both BSE Limited and the National Stock Exchange of India Ltd.

What the Numbers Show

The divergence between revenue growth (2%) and profit decline (5%) highlights the impact of both operational inefficiencies and one-off accounting adjustments. The ₹100 million sales reversal alone accounts for a significant portion of the missed revenue potential, suggesting that underlying demand may be stronger than the headline figure indicates. However, the compression in EBITDA margins from 30% to 27% signals persistent cost pressures from energy inputs that could weigh on profitability even as volumes recover.